Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. (LCTX) Revenue
Annual & quarterly revenue history · segment & region breakdown
LCTX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsLineage Cell Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.01B, an increase of 53.24% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.01B | +$0.01B | +53.24% |
| 2024-12-31 | $0.01B | +$0.00B | +6.19% |
| 2023-12-31 | $0.01B | -$0.01B | -39.16% |
| 2022-12-31 | $0.01B | +$0.01B | +277.39% |
| 2021-12-31 | $0.00B | +$0.00B | +404.01% |
| 2020-12-31 | $0.00B | -$0.00B | -47.70% |
| 2019-12-31 | $0.00B | +$0.00B | +4.38% |
| 2018-12-31 | $0.00B | -$0.00B | -20.98% |
| 2017-12-31 | $0.00B | -$0.00B | -20.43% |
| 2016-12-31 | $0.00B | -$0.00B | -11.13% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Lineage Cell Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Lineage Cell Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Lineage Cell Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
LCTX revenue · 4 questionsLCTX's trailing twelve-month (TTM) revenue is $0.01B. That is an increase of 53.24% year-over-year from $0.01B in FY2025.
▸ Source: FMP · Lineage Cell Therapeutics, Inc. SEC filings · GAAP · Lineage Cell Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026